Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

PURPOSE: Increased dosing frequency adversely affects treatment adherence and outcomes in chronic diseases; however, such data related to treatment adherence is lacking in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study compared adherence between patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiaoxiao, Emond, Bruno, Morrison, Laura, Kinkead, Frederic, Lefebvre, Patrick, Lafeuille, Marie-Hélène, Khan, Wasiulla, Wu, Linda H, Qureshi, Zaina P, Jacobs, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460580/
https://www.ncbi.nlm.nih.gov/pubmed/37641660
http://dx.doi.org/10.2147/PPA.S417180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460580/
https://www.ncbi.nlm.nih.gov/pubmed/37641660
http://dx.doi.org/10.2147/PPA.S417180

Ejemplares similares